vs
Alkermes plc.（ALKS）与Essex Property Trust（ESS）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是Alkermes plc.的1.2倍（$479.6M vs $384.5M），Essex Property Trust净利率更高（17.9% vs 12.8%，领先5.0%），Essex Property Trust同比增速更快（5.5% vs -10.6%），过去两年Essex Property Trust的营收复合增速更高（6.0% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
ALKS vs ESS — 直观对比
营收规模更大
ESS
是对方的1.2倍
$384.5M
营收增速更快
ESS
高出16.1%
-10.6%
净利率更高
ESS
高出5.0%
12.8%
两年增速更快
ESS
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $479.6M |
| 净利润 | $49.3M | $85.7M |
| 毛利率 | 88.0% | 70.0% |
| 营业利润率 | 15.1% | 31.7% |
| 净利率 | 12.8% | 17.9% |
| 营收同比 | -10.6% | 5.5% |
| 净利润同比 | -66.3% | -71.6% |
| 每股收益（稀释后） | $0.29 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSESS
| Q4 25 | $384.5M | $479.6M | ||
| Q3 25 | $394.2M | $473.3M | ||
| Q2 25 | $390.7M | $469.8M | ||
| Q1 25 | $306.5M | $464.6M | ||
| Q4 24 | $430.0M | $454.5M | ||
| Q3 24 | $378.1M | $450.7M | ||
| Q2 24 | $399.1M | $442.4M | ||
| Q1 24 | $350.4M | $426.9M |
净利润ALKSESS
| Q4 25 | $49.3M | $85.7M | ||
| Q3 25 | $82.8M | $172.7M | ||
| Q2 25 | $87.1M | $231.5M | ||
| Q1 25 | $22.5M | $212.8M | ||
| Q4 24 | $146.5M | $301.7M | ||
| Q3 24 | $92.4M | $125.5M | ||
| Q2 24 | $91.4M | $99.0M | ||
| Q1 24 | $36.8M | $285.1M |
毛利率ALKSESS
| Q4 25 | 88.0% | 70.0% | ||
| Q3 25 | 86.9% | 69.2% | ||
| Q2 25 | 87.3% | 70.7% | ||
| Q1 25 | 83.9% | 69.6% | ||
| Q4 24 | 85.6% | 70.0% | ||
| Q3 24 | 83.3% | 69.5% | ||
| Q2 24 | 84.6% | 70.8% | ||
| Q1 24 | 83.3% | 69.7% |
营业利润率ALKSESS
| Q4 25 | 15.1% | 31.7% | ||
| Q3 25 | 22.6% | 44.5% | ||
| Q2 25 | 23.8% | 59.5% | ||
| Q1 25 | 4.5% | 55.3% | ||
| Q4 24 | 37.8% | 67.0% | ||
| Q3 24 | 27.7% | 28.6% | ||
| Q2 24 | 27.5% | 31.1% | ||
| Q1 24 | 12.4% | 31.0% |
净利率ALKSESS
| Q4 25 | 12.8% | 17.9% | ||
| Q3 25 | 21.0% | 36.5% | ||
| Q2 25 | 22.3% | 49.3% | ||
| Q1 25 | 7.3% | 45.8% | ||
| Q4 24 | 34.1% | 66.4% | ||
| Q3 24 | 24.4% | 27.8% | ||
| Q2 24 | 22.9% | 22.4% | ||
| Q1 24 | 10.5% | 66.8% |
每股收益（稀释后）ALKSESS
| Q4 25 | $0.29 | $1.24 | ||
| Q3 25 | $0.49 | $2.56 | ||
| Q2 25 | $0.52 | $3.44 | ||
| Q1 25 | $0.13 | $3.16 | ||
| Q4 24 | $0.88 | $4.00 | ||
| Q3 24 | $0.55 | $1.84 | ||
| Q2 24 | $0.53 | $1.45 | ||
| Q1 24 | $0.21 | $4.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $76.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $5.5B |
| 总资产 | $2.5B | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSESS
| Q4 25 | $388.6M | $76.2M | ||
| Q3 25 | $616.4M | $66.0M | ||
| Q2 25 | $521.2M | $58.7M | ||
| Q1 25 | $399.8M | $98.7M | ||
| Q4 24 | $291.1M | $66.8M | ||
| Q3 24 | $396.3M | $71.3M | ||
| Q2 24 | $535.1M | $55.2M | ||
| Q1 24 | $420.8M | $499.0M |
总债务ALKSESS
| Q4 25 | — | — | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.6B |
股东权益ALKSESS
| Q4 25 | $1.8B | $5.5B | ||
| Q3 25 | $1.7B | $5.6B | ||
| Q2 25 | $1.6B | $5.6B | ||
| Q1 25 | $1.5B | $5.6B | ||
| Q4 24 | $1.5B | $5.5B | ||
| Q3 24 | $1.3B | $5.4B | ||
| Q2 24 | $1.3B | $5.5B | ||
| Q1 24 | $1.3B | $5.5B |
总资产ALKSESS
| Q4 25 | $2.5B | $13.2B | ||
| Q3 25 | $2.3B | $13.2B | ||
| Q2 25 | $2.3B | $13.2B | ||
| Q1 25 | $2.1B | $13.2B | ||
| Q4 24 | $2.1B | $12.9B | ||
| Q3 24 | $2.2B | $12.6B | ||
| Q2 24 | $2.2B | $12.5B | ||
| Q1 24 | $2.1B | $12.9B |
负债/权益比ALKSESS
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $1.1B |
| 自由现金流经营现金流 - 资本支出 | $170.0M | — |
| 自由现金流率自由现金流/营收 | 44.2% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 3.45× | 12.53× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSESS
| Q4 25 | $170.1M | $1.1B | ||
| Q3 25 | $101.7M | $342.6M | ||
| Q2 25 | $150.2M | $216.1M | ||
| Q1 25 | $98.8M | $281.5M | ||
| Q4 24 | $190.4M | $1.1B | ||
| Q3 24 | $81.6M | $316.2M | ||
| Q2 24 | $146.0M | $218.9M | ||
| Q1 24 | $21.1M | $314.9M |
自由现金流ALKSESS
| Q4 25 | $170.0M | — | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | — | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSESS
| Q4 25 | 44.2% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSESS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
现金转化率ALKSESS
| Q4 25 | 3.45× | 12.53× | ||
| Q3 25 | 1.23× | 1.98× | ||
| Q2 25 | 1.72× | 0.93× | ||
| Q1 25 | 4.40× | 1.32× | ||
| Q4 24 | 1.30× | 3.54× | ||
| Q3 24 | 0.88× | 2.52× | ||
| Q2 24 | 1.60× | 2.21× | ||
| Q1 24 | 0.57× | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
ESS
暂无分部数据
